Antiplatelet Drugs Market
Number of pages: 100 | Report Format: PDF | Published date: April 18, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
Market Size Value in 2022 |
US$ 2.12 Billion |
|
Market Size Value in 2031 |
US$ 4.18 Billion |
|
CAGR |
7.85% |
|
Base Year For Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Drug Class, Mode of Administration, Indication, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global antiplatelet drugs market was valued at US$ 2.12 billion in 2022 and is expected to register a revenue CAGR of 7.85% to reach US$ 4.18 billion by 2031.
Antiplatelet Drugs Market Fundamentals
Antiplatelet drugs are used to prevent the formation of blood clots or thrombosis by preventing platelets in the blood from aggregating or adhering together. These medications are typically used in conditions that raise the risk of blood clot formation, such as coronary artery diseases. Cardiovascular disorders, such as heart attacks and strokes, are a major source of morbidity and death worldwide. The rising incidence of risk factors such as obesity, diabetes, and hypertension, along with an aging population, gives a potential opportunity for antiplatelet drugs to be employed in the primary and secondary prevention of cardiovascular events. Additionally, trends in antiplatelet medications, such as personalized and combination therapy, have been breakthroughs in managing cardiovascular diseases, and their use is expected to increase during the forecast years. Top players are collaborating to launch such breakthrough technologies in the global antiplatelet drugs market.
Moreover, during the forecast period, market participants may look toward expanding the geographic reach of their antiplatelet drugs. This might include extending distribution networks, accessing new markets, and gaining regulatory clearances in developing nations. Furthermore, market participants may continue to spend in R&D to innovate and create new formulations with enhanced characteristics, such as extended-release formulations or unique drug delivery systems. Antiplatelet medications that have been enhanced may fetch higher prices and effective innovation that can boost revenue growth.
[11]
Antiplatelet Drugs Market Dynamics
A key factor supporting the global antiplatelet drugs market is its increasing demand for managing cardiovascular diseases such as acute coronary syndrome, ischemic stroke, and peripheral artery diseases. These diseases are the major cause of morbidity and mortality globally. According to the stats provided by the Centers for Disease Control and Prevention (CDC) in December 2022, peripheral artery diseases (PAD) affected 6.5 million people in the United States aged forty and more. The demand for antiplatelet medications as a preventative and therapeutic tool is predicted to continue strong as the prevalence of these disorders rises due to multiple risk factors such as an aging population, sedentary lifestyles, poor nutrition, and other comorbidities.
Increasing R&D initiatives by leading market players to develop antiplatelet medicines are expected to fuel market revenue growth during the forecast period. For example, PhaseBio Pharmaceuticals, Inc., a biopharmaceutical company, announced the full results of its Phase 2b clinical trial of bentracimab on April 2, 2022, during a Late Breaking Featured Clinical Research Presentation at the American College of Cardiology’s 71st Annual Scientific Session. Bentracimab is a recombinant human monoclonal antibody antigen-binding fragment intended to counteract the antiplatelet effect of ticagrelor in patients who have uncontrolled bleeding or require surgery.
Novel antiplatelet medicines are studied for their safety, effectiveness, and other characteristics. For instance, Johnson & Johnson stated in May 2022 that the findings of their XARELTO (rivaroxaban) registry and the acetylsalicylic acid (XATOA) registry were published in the European Heart Journal of the European Society of Cardiology. This study backs up XARELTO’s dual pathway-blocking involvement in individuals with coronary artery disease.
The restraining factor for the global antiplatelet drugs market is the excessive cost of these drugs and the side effects associated with their usage, which may limit their adoption and impact market revenue growth. However, increasing investments in research and development to develop safer and more effective antiplatelet drugs may present new opportunities for market players.
Antiplatelet Drugs Market Ecosystem
the global antiplatelet drugs market is analyzed from four perspectives: drug class, mode of administration, indication, and region.
Antiplatelet Drugs Market by Drug Class
Based on the drug class, the global antiplatelet drugs market is segmented into irreversible cyclooxygenase (COX) inhibitors, thromboxane inhibitors and phosphodiesterase inhibitors, adenosine diphosphate (ADP) receptor inhibitors, glycoprotein IIB/IIIA inhibitors, and others.
In 2022, the irreversible cyclooxygenase inhibitors segment dominated the global antiplatelet drugs market in terms of revenue share. The demand for irreversible cyclooxygenase inhibitors in antiplatelet drugs is increasing due to their ability to provide more potent and sustained inhibition of platelet aggregation compared to reversible inhibitors. This makes them particularly effective in preventing thrombotic events in patients with a high risk of cardiovascular disease.
ADP receptor inhibitors segment is expected to show high revenue growth during the forecast period. ADP receptor inhibitors are highly effective in preventing platelet aggregation and reducing the risk of thrombotic events. Moreover, they have a lower risk of bleeding than other antiplatelet drugs, making them a preferred choice for patients with high bleeding risk. Some common ADP receptor inhibitors include clopidogrel, prasugrel, and ticagrelor. These drugs are often used with aspirin to prevent cardiovascular events such as heart attack and stroke.
Antiplatelet Drugs Market by Route of Administration
[125]
Based on end-user, the global antiplatelet drugs market is segmented into oral and parenteral.
In 2022, the oral segment accounts for most of the global antiplatelet drugs market revenue share. Oral administration of antiplatelet drugs is preferred because it allows for a controlled and sustained release of the medication into the bloodstream, leading to better therapeutic outcomes and reduced risk of adverse effects. Additionally, oral administration is more convenient for patients than other routes.
The parenteral segment is expected to show lucrative revenue growth during the forecast period. Intravenous antiplatelet drugs prevent blood clots in patients with acute coronary syndrome and during percutaneous coronary intervention. Commonly used intravenous antiplatelet medicines include glycoprotein IIb/IIIa inhibitors and cangrelor, effectively reducing the incidence of major adverse cardiovascular events. However, these drugs can also increase the risk of bleeding and should be used cautiously in patients with a history of bleeding disorders or recent surgery.
Antiplatelet Drugs Market by Indications
Based on indications, the global antiplatelet drugs market is segmented into acute coronary syndrome, acute ischemia stroke, arterial thrombosis, and others.
Acute coronary syndrome accounted for the majority of revenue share in 2022. Antiplatelet drugs are an essential component in the management of acute coronary syndrome. These drugs include aspirin, clopidogrel, and ticagrelor, often used to provide optimal protection against thrombotic events. Moreover, the rising prevalence of acute coronary syndrome is expected to increase the demand for antiplatelet drugs.
However, the acute ischemia stroke segment is expected to increase during the forecast period. This revenue growth can be attributed to the rising prevalence of stroke incidents globally and the increasing demand for effective treatment options for acute ischemic stroke. Developing novel antiplatelet drugs is also expected to drive market revenue growth in this segment.
Antiplatelet Drugs Market by Region
Based on region, the global antiplatelet drugs market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America accounted for the highest revenue share in 2022. This is attributed to the increasing prevalence of cardiovascular diseases and the growing geriatric population. Technological advancements in drug delivery systems and a rise in healthcare expenditure also contribute to market revenue growth. Moreover, The market revenue growth is expected to be further fueled by the increasing demand for personalized medicine and the development of innovative therapies for cardiovascular diseases. Furthermore, the emergence of new players in North America will likely create lucrative revenue growth opportunities during the forecast period.
Several key players and high competition characterize the European antiplatelet drugs market. The market revenue is expected to grow significantly due to the increasing prevalence of cardiovascular diseases and the rising geriatric population in the region. Furthermore, the growing demand for advanced and innovative antiplatelet drugs and the rising investments in research and development activities are also expected to drive market revenue growth during the forecast period. However, stringent regulatory policies and the high costs of these drugs may hinder market revenue growth.
The Asia Pacific antiplatelet drugs market revenue is expected to grow significantly during the forecast period due to the rising prevalence of cardiovascular diseases and the increasing geriatric population. Adopting advanced technologies and increasing healthcare expenditure are also expected to contribute to market revenue growth.
Antiplatelet Drugs Market Competitive Landscape
The competitive scenario of the antiplatelet drugs market is highly dynamic, with numerous players. Market players in the global antiplatelet drugs market focus on expanding their product portfolio and investing in research and development activities. These companies also focus on strategic collaborations and partnerships to expand their market presence and increase revenue.
The prominent companies having the largest revenue share in the global antiplatelet drugs market are,
Antiplatelet Drugs Market Recent Developments
One of the growth opportunities for the global antiplatelet drugs market is the introduction of novel antiplatelet drugs and increasing research and development activities.
According to the deep-dive market assessment study by Growth Plus Reports, the global antiplatelet drugs market was valued at US$ 2.12 billion in 2022.
Some major strategies key market players adopt in the antiplatelet drugs market include mergers and acquisitions, partnerships and collaborations, and product launches. These strategies help companies to expand their product portfolio, strengthen their market position, and enhance their geographic presence.
Based on indications, the global antiplatelet drugs market is segmented into acute coronary syndrome, acute ischemia stroke, arterial thrombosis, and others. Acute coronary syndrome accounted for the majority of revenue share in 2022.
The global antiplatelet drugs market is expected to register a CAGR of 7.85% during the forecast period.
*Insights on financial performance are subject to the availability of information in the public domain